Positive data from planned interim analysis of COSMIC-311 phase 3 trial of cabozantinib (Cabometyx) in patients with previously treated radioiodine-refractory thyroid cancer

Interim analysis (n=300) found that cabozantinib significantly improved progression-free survival versus placebo (risk of disease progression or death reduced by 78% (HR 0.22; 96% CI 0.13 – 0.36; p<0.0001). Detailed results will be submitted at a future medical conference.

SPS commentary:

Currently in UK, Cabometyx is licensed only for treatment of advanced renal cell & hepatocellular carcinoma; and the other brand product of cabozantinib (Cometriq®) is licensed for treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Biospace Inc.